

Aalborg Universitet

Editorial: RNA-chromatin interactions: Biology, mechanism, disease and therapeutics

Mathiyalagan, Prabhu; Martelotto, Luciano G.; Ounzain, Samir; El-Osta, Assam; Uchida, Shizuka

Published in: Frontiers in Genetics

DOI (link to publication from Publisher): 10.3389/fgene.2022.1069427

Creative Commons License CC BY 4.0

Publication date: 2023

Document Version Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):

Mathiyalagan, P., Martelotto, L. G., Ounzain, S., El-Osta, A., & Uchida, S. (2023). Editorial: RNA-chromatin interactions: Biology, mechanism, disease and therapeutics. *Frontiers in Genetics*, *13*, Article 1069427. https://doi.org/10.3389/fgene.2022.1069427

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
 You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from vbn.aau.dk on: December 04, 2025





OPEN ACCESS

EDITED BY
William C. Cho,
QEH, Hong Kong SAR, China

REVIEWED BY Nick Gilbert, University of Edinburgh, United Kingdom

*CORRESPONDENCE
Prabhu Mathiyalagan,

☑ prabhu.gene@gmail.com

Central, Houston, TX, USA

Frontiers in Genetics

†PRESENT ADDRESS Prabhu Mathiyalagan, Benthos Prime

SPECIALTY SECTION

This article was submitted to RNA, a section of the journal

RECEIVED 13 October 2022 ACCEPTED 23 December 2022 PUBLISHED 12 January 2023

CITATION

Mathiyalagan P, Martelotto LG, Ounzain S, El-Osta A and Uchida S (2023), Editorial: RNA-chromatin interactions: Biology, mechanism, disease and therapeutics. *Front. Genet.* 13:1069427. doi: 10.3389/fgene.2022.1069427

COPYRIGHT

© 2023 Mathiyalagan, Martelotto, Ounzain, El-Osta and Uchida. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: RNA-chromatin interactions: Biology, mechanism, disease and therapeutics

Prabhu Mathiyalagan¹*[†], Luciano G. Martelotto², Samir Ounzain³, Assam El-Osta⁴ and Shizuka Uchida⁵

¹Center for Human Genetics and Genomics, New York University, New York City, NY, United States, ²Adelaide Centre for Epigenetics, South Australian Immunogenomics Cancer Institute, The University of Adelaide, Adelaide, SA, Australia, ³HAYA Therapeutics, Lausanne, Switzerland, ⁴Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia, ⁵Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

KEAMUBDS

ncRNA (non-coding RNA), RNA, chromatin, transcription, epitranscriptome

Editorial on the Research Topic

RNA-chromatin interactions: Biology, mechanism, disease and therapeutics

Introduction

From the development to disease, long non-coding RNAs (lncRNAs) regulate chromatin landscape ultimately influencing gene transcription, X-chromosome inactivation, RNA-mediated epigenetic inheritance, DNA methylation and genome stability through maintenance of active and silent chromatin state. LncRNAs function through establishing and maintaining stable RNA-chromatin interactions at a specific genomic locus through RNA-protein and/or RNA-DNA interactions. Growing evidence underscores the significance of lncRNA sequence, structure and epitranscriptomic modifications as potential mediators of RNA-chromatin interactions. Whether lncRNA sequence, structure and epitranscriptomic marks, either alone or in a particular combination, act as specific molecular code governing RNA-chromatin interactions needs to be elucidated. The future of lncRNA research and its therapeutic success relies on mapping the interplay among lncRNA sequence, structure and epitranscriptome. Further, it is important to understand how these features, alone or in a particular combination, stabilize RNA-chromatin interactions ultimately influencing gene expression and function.

Non-coding RNAs space it up

As we enter the space age, it is important to understand how the non-gravitational environment affects our health (Demontis et al., 2017) In this regard, Bisserier et al. provide novel insights into potential roles of exosomal lncRNAs in determining the effects of radiation after spaceflight. As exosomal RNAs are known to mediate cellular communication, Bisserier et al. provide new experimental data on exosomal RNAs obtained from peripheral blood plasma of three astronauts who flew on various shuttle missions between 1998 and 2001. In their transcriptome analysis of exosomal RNAs during spaceflight, they report several

Mathiyalagan et al. 10.3389/fgene.2022.1069427

differentially expressed lncRNAs in exosomes isolated from astronauts at different timepoints during their spaceflight. These results also provide new insights into the diagnostic and prognostic value of astronauts-derived exosomal lncRNAs as emerging ncRNA biomarkers and highlight the potential role for exosomal lncRNAs in health risks associated with spaceflight.

Non-coding RNAs at the center of liquidliquid phase separation

For a biochemical reaction to occur in a cell, the interacting partners must be present in the close proximity (Stanton et al., 2018). To address this point, Somasundaram et al. provides an in-depth analysis of lncRNAs with specific focus on their role in establishing and maintaining biomolecular phase-separation. Formation membrane-free ribonucleoprotein condensates resulting intracellular compartments by liquid-liquid phase separation or condensation is a critical phenomenon that compartmentalizes lncRNA and other macromolecules separate from others. In this Review article, Somasundaram et al. further provides a deeper understanding of phase separation, physio-chemical properties of such biomolecular condensates, their composition and the role of RNAs in driving the formation and stabilization of biomolecular condensates. Particularly, the Review highlights several lncRNAs, which are known to act as "the anchor" using their specific intrinsic sequence motifs within the condensates. Furthermore, the authors provide some recent evidence for lncRNAs working through phase separation in association with diseases, such as cancer, further highlighting the significance of condensate biology in cellular physiology and argue why better understanding of condensates would enhance therapy. Taken together, this review article is an excellent addition and an insightful summary of new developments in the field of ncRNA and phase separation.

Epitranscriptome connects the noncoding and coding transcriptomes

To date, over 170 RNA modifications are known across organisms (Boccaletto et al., 2018), which opened up a new field of study called epitranscriptomics. As epitranscriptomic marks are found in all types of RNA, there is a growing interest to study how epitranscriptomic marks influence the functions of lncRNAs. To introduce readers to this new existing field of study from the perspective of lncRNAs, Lee O. Vaasjo summarizes chemical changes to RNA as a critical regulator of mRNA regulation. RNA modifications, particularly in the form of N6methyladenosine (m⁶A) methylation, have been shown to be integral for RNA metabolisms of mRNAs and for several lncRNAs. For mRNAs, m⁶A modifications are specifically regulated through distinct mechanisms occurring within 3'-UTR or coding regions. However, little is known on how m⁶A modifications are regulated within 5'-UTRs of mRNAs. In this Research Topic, Vaasjo summarizes elegantly how m⁶A methylation regulates 5'-UTRs of mRNA through lncRNAs. Specifically, the author provides recent examples on how several lncRNAs can target specific sites within 5'-UTRs of mRNAs to regulate m⁶A patterning within 5'-UTRs of mRNAs. Furthermore, the author highlights a critical epigenetic crosstalk mediated by lncRNAs through direct interactions of lncRNAs with chromatin remodeling proteins in determining m⁶A pattern within 5'-UTRs of mRNAs. This *Review* highlights an important crosstalk occurring between lncRNAs and the m⁶A modifying machinery in the nucleus; addressing one of the key mechanisms by which lncRNAs not only working at the level of gene expression but also at the epitranscriptomics level thereby regulating the expression of coding transcriptome. This *Review* can be regarded as an excellent summary of novel findings that underscores an important interplay between the non-coding (ncRNA) transcriptome and the coding (mRNA) transcriptome through complex regulation of epitranscriptomic mechanisms.

RNA-modifying enzymes and RNAbinding proteins at the heart of mitochondria

Mitochondria are dynamic powerhouses of the cell that are important for many cellular activities (Tilokani et al., 2018). As the heart must work restlessly to sustain the life of an organism, the proper functionality of mitochondria is essential as dysregulation of mitochondrial functions lead to heart failure. Ziemann et al. tackles the problem of identifying ncRNAs and RNA-binding proteins (RBPs) that may be associated with hearts of dilated cardiomyopathy (DCM). Ziemann et al. report significant changes in expression of several genes encoding ncRNAs, such as ribosomal RNAs (rRNA), and further classify that downregulation of several RBPs as a specific feature of hearts in DCM. Although roles for majority of ncRNAs remain unexplored in mature adult tissues, such as in the heart, Ziemann et al. elegantly show that dysregulated expressions of several RBPs are present in hearts of DCM. In particular, the changes were observed in expression for gene sets of mitochondrial (mt)-rRNA processing, aminoacyl-tRNA synthases, and mitoribosome subunits for in-situ protein synthesis. The authors identified several enzymes such as mitochondrial rRNA methyltransferases (e.g., Mrm1-3, Nsun4 and Trmt10c) that regulate rRNA epitranscriptome and mitochondrial ribonucleases (e.g., Prorp, Elac2) as differentially regulated genes in DCM. Whether these changes in expression to rRNA methyltransferases and RNases have transcriptome-wide impact on coding and non-coding RNAs needs further investigation. Interestingly, Ziemann et al. report downregulation of several mtRBPs, including Slirp, Gadd45GIP1, Dap3, Ptcd1-3, Lrpprc, Grsf1 etc, which are involved in rRNA modification and formation of mitoribosome. However, how these RBPs influence the pathophysiology of DCM remains unknown. Together, these new results from Ziemann et al. provide important new evidence indicating changes in expression of enzymes and proteins potentially involved in ribosomal epitranscriptome in DCM hearts.

Conclusion

In summary, this Research Topic provides an important overview on RNA-based molecular mechanisms that are not only of fundamental importance but also of therapeutics. Research articles as well as Reviews published in this Research Topic cover a broad range of mechanisms involving RNA-chromatin interactions. These mechanisms provide important insights to uncover ncRNA function and a deeper understanding of RNA-chromatin interactions will undoubtedly begin a new era in RNA-based therapeutics.

Mathiyalagan et al. 10.3389/fgene.2022.1069427

Author contributions

PM wrote the manuscript. All other authors provided edits and approved the manuscript.

Conflict of interest

SO is co-founder and Chief Executive Officer of HAYA Therapeutics. PM is co-founder and Chief Executive Officer of Benthos Prime Central, Houston, TX, United States.

References

Boccaletto, P., Machnicka, M. A., Purta, E., Piatkowski, P., Baginski, B., Wirecki, T. K., et al. (2018). Modomics: A database of RNA modification pathways. 2017 update. *Nucleic Acids Res.* 46, D303–D307. doi:10.1093/nar/gkx1030

Demontis, G. C., Germani, M. M., Caiani, E. G., Barravecchia, I., Passino, C., and Angeloni, D. (2017). Human pathophysiological adaptations to the space environment. *Front. Physiol.* 8, 547. doi:10.3389/fphys.2017.00547

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Stanton, B. Z., Chory, E. J., and Crabtree, G. R. (2018). Chemically induced proximity in biology and medicine. *Science* 359, eaao5902. doi:10.1126/science. aao5902

Tilokani, L., Nagashima, S., Paupe, V., and Prudent, J. (2018). Mitochondrial dynamics: Overview of molecular mechanisms. *Essays Biochem.* 62, 341–360. doi:10.1042/EBC20170104